Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

In contrast to the findings in a recent report, large doses of salicylate did not consistently slow the thyroidal release of 131I in patients with thyrotoxicosis. In 7 patients who received salicylate, and in 4 tests in which noncalorigenic congeners of salicylate (gentisate and gamma-resorcylate) were administered, slowing of thyroidal release of 131I was observed in only 2, and in both this change was very slight. In the remaining 9 studies, salicylate or its congeners either did not change or appeared to increase thyroidal 131I release rates. Since large therapeutic doses of 131I had been given to the patients in the previous study, it seems possible that the slowing of 131I release observed was due to an inhibition by salicylate of radiation thyroiditis. In all the patients, a decrease in the PBI occurred during the administration of salicylate or its congeners. This decrease could be ascribed largely to the selective inhibition of thyroxine binding by prealbumin which was evident in all the patients during administration of these compounds.

This content is only available as a PDF.
Copyright © 1964 by The Endocrine Society
You do not currently have access to this article.
Download all slides